|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
+0.18% | +1.27% |
| 06-19 | Sanofi Receives Approval for Sarclisa Subcutaneous Formulation in Japan for Multiple Myeloma | CI |
| 06-19 | Japan gives the green light to Sanofi's Sarclisa SC in multiple myeloma |  |
| Market Cap | 88.98B 102B 82.33B 77.12B 144B 9,627B 145B 978B 379B 4,739B 383B 375B 16,462B | P/E 2026 * |
11x | P/E 2027 * | 10.3x |
|---|---|---|---|---|---|
| Enterprise Value | 99.79B 114B 92.33B 86.48B 162B 10,796B 163B 1,097B 425B 5,314B 430B 420B 18,460B | EV / Sales 2026 * |
2.12x | EV / Sales 2027 * | 1.94x |
| Free-Float |
89% | Yield 2026 * |
5.74% | Yield 2027 * | 6.08% |
Last Transcript: Sanofi
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 2023-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 56 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 64 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.18% | - | - | 102B | |
| -1.21% | -3.04% | +44.03% | +143.07% | 980B | |
| -2.48% | -5.18% | +52.47% | +39.15% | 550B | |
| -2.14% | -4.94% | +16.83% | +57.08% | 382B | |
| +0.25% | -3.09% | +23.33% | +16.04% | 316B | |
| +0.61% | -1.69% | +25.42% | +13.64% | 272B | |
| +0.22% | -3.10% | +24.67% | +30.49% | 268B | |
| +4.59% | +1.98% | -38.43% | -46.26% | 199B | |
| -1.19% | -4.95% | +16.68% | +47.69% | 182B | |
| -1.35% | -1.46% | +14.06% | +59.26% | 154B | |
| Average | -0.27% | -3.02% | +19.90% | +40.02% | 366.93B | |
| Weighted average by Cap. | -0.76% | -3.68% | +29.33% | +63.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.07B 53.98B 43.55B 40.79B 76.37B 5,092B 76.95B 517B 200B 2,506B 203B 198B 8,707B | 49.98B 57.32B 46.24B 43.31B 81.09B 5,407B 81.71B 549B 213B 2,662B 215B 210B 9,246B |
| Net income | 8.15B 9.34B 7.54B 7.06B 13.22B 881B 13.32B 89.53B 34.66B 434B 35.06B 34.3B 1,507B | 8.95B 10.27B 8.29B 7.76B 14.53B 969B 14.64B 98.43B 38.11B 477B 38.54B 37.71B 1,657B |
| Net Debt | 10.8B 12.39B 10B 9.36B 17.53B 1,169B 17.66B 119B 45.98B 575B 46.5B 45.5B 1,999B | 8.08B 9.27B 7.48B 7.01B 13.12B 875B 13.21B 88.85B 34.4B 430B 34.79B 34.04B 1,495B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
- GCVRZ Stock
Select your edition
All financial news and data tailored to specific country editions
